Table 1.
Participant demographic information.
| Low PA (n = 18) | High PA (n = 22) | Statistics | |||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Age (years) | 24.06 | 7.78 | 23.41 | 3.91 | t(38) =0.34, p = 0.735 |
| Education (years) | 16.11 | 2.76 | 16.77 | 2.83 | t(38) = −0.74, p = 0.462 |
| Ethnicity (C/NC) | 1/17 | 1/21 | χ2(1) = 0.021, p =0.884 | ||
| BMI (kg/m2) | 21.88 | 2.60 | 23.40 | 3.30 | t(38) = −1.58, p = 0.122 |
| Hormonal contraceptive use (Y/N) | 9/9 | 12/10 | χ2(1) = 0.082, p = 0.775 | ||
| Menstrual phase placebo (F/M/L) | 8/5/5 | 8/6/8 | χ2(2) = 0.387, p = 0.824 | ||
| Menstrual phase drug (F/M/L) | 6/5/7 | 10/8/4 | χ2(2) = 2.132, p = 0.344 | ||
| Side effects (Y/N) | 8/10 | 11/11 | χ2(1) = 0.123, p = 0.726 | ||
| Correct treatment guess (Y/N) | 14/4 | 14/8 | χ2(1) = 0.943, p = 0.332 | ||
| AUDIT total (SD) | 6.11 (4.13) | 6.45 (5.32) | t(38) = −0.224, p = 0.824 | ||
| Smoking (Y/N) | 0/18 | 0/22 | n/a | ||
| PHQ-9 (SD) | 1.61 (1.20) | 1.45 (1.22) | t(38) = 0.407, p = 0.686 | ||
| GAD-7 (SD) | 0.72 (0.895) | 1.41 (1.26) | t(38) = −1.945, p = 0.059 | ||
| IPAQ (mins/wk) | |||||
| Vigorous intensity activity | 30.28 | 58.37 | 207.05 | 94.30 | t(38) = −6.93, p < 0.001 (one-tailed), d = 2.26 |
| Moderate intensity activity | 206.11 | 230.12 | 278.41 | 222.43 | t(38) = −1.01, p = 0.320 |
| Walking | 461.94 | 297.85 | 457.50 | 284.12 | t(38) = 0.05, p = 0.962 |
| Sitting | 366.67 | 180.75 | 351.82 | 153.30 | t(38) = 0.28, p = 0.780 |
| Total physical activity | 698.33 | 428.23 | 942.94 | 408.14 | t(38) = −1.85, p = 0.073 |
| Energy expenditure, METs-min/week | 2620.53 | 1650.94 | 4546.11 | 1793.27 | t(38) = −3.50, p = 0.001, d = 1.12 |
| Resting HR | 71.78 | 8.56 | 66.14 | 14.10 | t(38) = 1.71, p = 0.048 (one-tailed), d = 0.55 |
Abbreviations
- PA
physical activity
- BMI
body mass index
- PHQ-9
patient health questionnaire
- GAD-7
generalised anxiety disorder screener
- IPAQ
international physical activity questionnaire
- MET
metabolic equivalent task.